Arrowhead Research (ARWR) Completes Enrollment in First Cohort of ARC-520 Phase 2a
Tweet Send to a Friend
Arrowhead Research Corporation (Nasdaq: ARWR) announced that the first cohort of 8 patients has been fully enrolled and dosed in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
